Semaglutide Contraindications & Boxed Warnings

Overview

Semaglutide (Ozempic and Wegovy) carries an FDA boxed warning regarding the risk of thyroid C-cell tumors based on rodent studies. Several patient populations have absolute or relative contraindications, and clinical judgment is required for many borderline situations. The information below summarizes the FDA prescribing information; final treatment decisions belong to a licensed clinician with access to the patient's full history.

Absolute contraindications

• Personal or family history of medullary thyroid carcinoma (MTC). Semaglutide caused thyroid C-cell tumors in rodents at clinically relevant exposures; relevance to humans is not established but the boxed warning is conservative.
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients with MEN 2 are at increased risk of MTC.
• Known serious hypersensitivity to semaglutide or any of the product excipients.
• Pregnancy. Animal reproduction studies showed adverse fetal effects. Wegovy and similar GLP-1s carry the same precaution. Manufacturers recommend discontinuing semaglutide at least 2 months before a planned pregnancy due to the drug's long half-life.

Relative contraindications and special caution

• Severe gastroparesis or pre-existing severe gastrointestinal disease. Semaglutide slows gastric emptying, which may worsen pre-existing motility disorders.
• History of pancreatitis. GLP-1 receptor agonists have been associated with pancreatitis in post-marketing surveillance; patients with prior pancreatitis require careful risk-benefit assessment.
• Active diabetic retinopathy. Rapid glycemic improvement may transiently worsen retinopathy. Ophthalmologic monitoring is appropriate.
• Severe renal impairment (eGFR <30 mL/min/1.73 m²). Use with caution; dehydration from GI side effects can precipitate further decline.
• Concurrent use of insulin or sulfonylureas. Increases hypoglycemia risk; dose adjustment of the concurrent medication is typically required.
• Severe hepatic impairment. Limited data; use with clinical caution.
• Breastfeeding. Excretion in human milk is not well characterized; benefit-risk discussion required.

Drug interactions to evaluate

Semaglutide delays gastric emptying, which may affect the absorption of orally administered medications taken at the same time. The most clinically relevant interactions involve hormonal contraceptives — patients on oral contraceptives may have reduced contraceptive efficacy during semaglutide initiation and titration. Switching to a non-oral contraceptive (such as intrauterine device, implant, injection, or transdermal) or adding a barrier method for the four weeks after initiation and after each dose escalation is the FDA-recommended approach. Other narrow-therapeutic-index oral medications (such as warfarin, levothyroxine, and certain anti-seizure drugs) may warrant monitoring during initiation.

Monitoring during therapy

Recommended monitoring includes baseline and periodic assessment of: renal function (eGFR), liver enzymes, fasting glucose and HbA1c (in patients with diabetes or prediabetes), thyroid examination if clinically indicated, gallbladder symptoms, signs and symptoms of pancreatitis, depression and suicidal ideation (mood monitoring is part of the labeled precautions for GLP-1 weight management products), and pregnancy status in patients of reproductive potential.

Frequently asked questions

Can I take semaglutide if I have a thyroid nodule?

A thyroid nodule alone is not an absolute contraindication. The boxed warning addresses medullary thyroid carcinoma specifically. Patients with thyroid nodules should have appropriate workup (typically ultrasound and biopsy when indicated) before starting any GLP-1 receptor agonist.

What if I have a family history of thyroid cancer but not MTC specifically?

Most thyroid cancers (papillary, follicular) are not medullary. The boxed warning specifically addresses MTC and MEN 2. A family history of non-medullary thyroid cancer is not an absolute contraindication, but clinical history should be reviewed in detail.

Can semaglutide be used in patients with type 1 diabetes?

Semaglutide is not FDA-approved for type 1 diabetes. Some off-label use exists in clinical practice as an adjunct to insulin in selected patients with obesity, but this is investigational and requires close monitoring.